Medicare forces drug plans to favor cheap generics over brand names
H.R. 8143 — Ensuring Access to Lower-Cost Medicines for Seniors Act of 2026. · Filed by Doris Matsui (D-CA) · 2 cosponsors · Introduced Mar 27, 2026 · Referred to committee
Your members of Congress
Enter a ZIP to see where your representative and both senators stood on this bill.
Looked up on this device — your ZIP is never stored on our servers.
What it does
This bill requires Medicare Part D prescription drug plans to place lower-cost generic drugs and biosimilars in preferred (cheaper) formulary tiers and prohibits insurance companies from using prior authorization or step therapy to discourage seniors from choosing these lower-cost options. The goal is to reduce out-of-pocket costs for seniors by making cheaper alternatives more accessible than brand-name drugs, even if the brand drug is clinically equivalent.
Why we flagged it
The bill mandates that Medicare Part D prescription drug plans include lower-cost generic drugs and biosimilars in preferred formulary positions, with restrictions on utilization management barriers. This is substantive healthcare cost-containment policy affecting senior drug access and pricing.
What the text implies
- Formulary tier placement and cost-sharing rules directly affect which drugs seniors choose, potentially shifting demand away from brand-name drugs toward generics/biosimilars regardless of clinical preference.
- Prohibition on step therapy and prior authorization for lower-cost alternatives may reduce PDP sponsors' ability to manage utilization and control total plan costs, potentially increasing premiums or reducing plan profitability.
The full analysis lists 5 implications of this text.
Who stands to gain
generic drug manufacturers; biosimilar manufacturers; pharmacy benefit managers (PBMs) managing formularies